SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 17, 2020
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of Incorporation)
|
|
|
|
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760 ) 931-9200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
|
Emerging growth company
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 |
Entry into a Material Definitive Agreement.
|
Reference is made to the information set forth in item 5.02 below.
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On December 17, 2020, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that its founder and executive chairman Stanley T. Crooke, M.D.,
Ph.D., will retire from the Company and its board of directors effective June 2021. Dr. Crooke is stepping down so that he may focus on his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation.
Pursuant to a consulting agreement, Dr. Crooke will continue to serve as a scientific advisor to the Company including providing advice regarding the Company’s research
and development programs and guiding the core antisense research group he founded at the Company.
A copy of the release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
|
Item 9.01.
|
Exhibits.
|
(d) Exhibits.
|
Exhibit No.
|
Description
|
|
|
Press Release dated December 17, 2020.
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Ionis Pharmaceuticals, Inc.
|
||
|
Dated: December 17, 2020
|
By:
|
/s/ Patrick R. O’Neil
|
|
Patrick R. O’Neil
|
||
|
Executive Vice President, Legal, General Counsel and Chief Compliance Officer
|
||
Exhibit 99.1
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
CARLSBAD, Calif., Dec. 17, 2020 – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the
leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Crooke, M.D., Ph.D., will retire from Ionis and its board of directors effective June 2021. Dr. Crooke is stepping down so that he may focus on
his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation. Dr. Crooke will continue to serve as a scientific advisor to Ionis including providing advice regarding Ionis’ research and development programs and guiding
the core antisense research group he founded at Ionis.
Dr. Crooke founded Ionis more than 30 years ago and is credited with being the pioneer of RNA-targeted therapeutics. Under his leadership, Ionis developed its novel
antisense technology and created one of the largest, most advanced pipelines in the industry. He has personally led the development of more than 20 marketed drugs throughout his career and supported the creation and growth of several companies based
on Ionis’ antisense technology. In addition, Dr. Crooke is responsible for creating one of the most innovative and scientifically driven cultures that has an unwavering passion for discovering and developing future-creating therapies and a steadfast
commitment to saying yes to the patients who are depending on them.
“The brilliance of Stan’s vision isn’t just represented by the founding and success of Ionis, but it is also reflected in his creation of an entirely new chemical class of
medicines, antisense oligonucleotides,” said Joseph Loscalzo, M.D., Ph.D., head, Department of Medicine and Physician-in-Chief, Brigham & Woman’s Hospital, Harvard Medical School and Ionis board member. “His scientific contributions will no doubt
continue to provide extraordinary benefit to the healthcare industry and the many patients who once were told there isn’t any hope or treatment for their disease. With Stan solely focusing on his scientific interests and n-Lorem, we can only expect
his impact to continue.”
Dr. Crooke has received numerous honors and awards for his pioneering work in RNA-targeted therapeutics
including the prestigious Massry Prize, the Oligonucleotide Therapeutics Society Lifetime Achievement Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Prix Galien Best
Biotechnology Award for Spinraza, the Scrip Lifetime Achievement Award, and BIO’s Helix Award for the most important innovation. In addition, Ionis’ board of directors named the main headquarters building in honor of Dr. Crooke in 2019 to
recognize his extraordinary role in creating Ionis. Dr. Crooke has published nearly 600 scientific publications, edited more than 20 books, and is a named inventor on numerous patents.
“Thanks to Stan’s vision and perseverance, thousands of patients are benefiting from the transformative and life-changing antisense medicines discovered and developed by
Ionis, said Brett P. Monia, Ph.D., Ionis chief executive officer. “We are pleased that Stan will continue to provide advice and counsel to Ionis and applaud his efforts to use the technology that was created at Ionis to bring hope and therapies to
the patients who will benefit greatly from the n-Lorem foundation.”
n-Lorem Foundation, founded in 2019 by Dr. Crooke and initially funded by him, his wife Dr. Rosanne Crooke, Ionis and Biogen, provides free individualized antisense
treatments to patients living with ultra-rare diseases (1 to 30 patients worldwide) for life. In less than a year of its founding, the Foundation has garnered support from global partners such as the Korean Institute of Toxicology, many donors, has
received more than 40 requests for treatment and has 10 patients being treated or about to be treated with an investigational antisense medicine that was designed for each one’s specific genetic mutation that’s causing their disease.
About Ionis Pharmaceuticals, Inc.
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that
can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved
treatment for all patients, children and adults with spinal muscular atrophy, as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set
on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D.
Vice President, Investor Relations
760-603-2741
Ionis Pharmaceuticals Media Contact:
Roslyn Patterson
Vice President, Marketing and Communications
760-603-4679